Bambusa Therapeutics makes its trading debut after pricing an upsized US initial public offering. Bloomberg reports the dermatology-focused biotech’s shares slide about 7% on debut, following an IPO that raises $168.9 million. The company is described as early-stage and focused on dermatology and autoimmune diseases, with a clinical-stage pipeline aimed at immunology and inflammation.
Other coverage emphasizes the deal mechanics rather than post-listing performance. PR Newswire announces the pricing of the upsized IPO for Bambusa Therapeutics, framing the offering as part of its development of long-acting precision bispecific antibodies. Seeking Alpha also reports the IPO pricing, including that it is priced at $16 per share and is upsized, though its provided summary is not detailed.
Across outlets, the main shared point is that Bambusa Therapeutics completes an upsized IPO priced at $16 per share and proceeds to list, with Bloomberg adding the first-day market reaction while PR Newswire focuses on corporate announcement language.
